Drug Discovery and Nanomedicine Research Program
The Drug Discovery and Nanomedicine Research Program at the Saint John’s Cancer Institute fosters the development of novel, safe and effective therapeutics for both oral and intravenous delivery, to address unmet disease needs in oncology and the neurosciences.
Mission and Vision
The Drug Discovery and Nanomedicne (DDNM) research program utilizes a unique, two-pronged approach, combining drug discovery and nanotechnology tools to circumvent existing clinical problems in Cancer, Neurodegenerative Diseases and Neurological Disorders. The DDNM research program plays a critical role at Saint John’s Cancer Institute and PNI by facilitating the transition of lab-based discoveries into truly personalized treatments, providing core expertise in drug discovery and nanotechnology tools.
Our DDNM research program is part of the Department of Translational Neurosciences, located on the 2nd floor of Saint John’s Cancer Institute. Our laboratories are fully equipped with state-of-the-art instruments to ensure quality work. We also maximize our productivity through multi-disciplinary collaboration and fostering a teamwork-based approach.Learn More
Partnership & Collaboration
The Drug Discovery and Nanomedicne (DDNM) program has strong support from collaborating partners on multiple pilot projects, securing grants from both private as well as public agencies.Learn More
Current Research Topics
The Drug Discovery and Nanomedicine program is staffed with full-time scientists and technicians, many of whom are seasoned experts in distinct aspects of drug discovery and nanomedicine research.Learn More